Skip to NavigationSkip to content

Top Ten most popular articles on Pharmafile.com this week

Published on 06/03/20 at 12:16pm

The coronavirus continues to threaten the global drug supply line, with disruption to the US drug production pipeline from the coronavirus potentially hurting its domestic supply of 150 drugs. Factoring into this, is India setting out to reduce exports of active pharmaceutical ingredients (APIs) until further notice, due to fears of internal drug shortages that could occur from coronavirus.

In China, the government has moved to authorise Roche’s Actemra (tocilizumab) as a treatment for severe complications from contracting the COVID-19 coronavirus in a bid to contain the ongoing national and global outbreak of the virus.

10. MSD's Phase 3 study of lymphoma treatment meets primary endpoints

MSD announced that its Phase 3 study of Keytruda (pembrolizumab) for the treatment of adults with relapsed or refractory classical Hodgkin lymphoma (cHL) met one of its dual primary endpoints of progression-free survival.

9. New study calculates median drug development costs at circa $1 billion

New research has pinned a concrete figure on the perennial industry question: how much does it cost to bring a new drug product through development to market?

8. US Judge rules that a decade of unpublished trial results must be made public

A federal judge in New York’s Southern District has ruled that 10 years of unpublished clinical trial data must now be made public – a judgement which could have vast implications for possibly over 1,000 unpublished studies between 2007 and 2017.

7. Takeda's subcutaneous vedolizumab nabs CHMP nod for maintenance of ulcerative colitis and Crohn's

Takeda’s subcutaneous formulation of its gut-selective biologic vedolizumab has secured recommendation from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), it has emerged, which advocated for its use as a maintenance treatment for Moderate to severely active ulcerative colitis (UC) or Crohn’s disease (CD).

6. Big Pharma more profitable than most public firms

Large pharmaceutical companies make a much larger profit than most other public companies, according to a new study.

5. Researchers have tested CRISPR gene editing inside a person’s body for the first time

Allergan and Editas Medicine have treated their first patient in a clinical trial with CRISPR gene editing.

4. GW Pharma takes back control of UK Sativex sales from Bayer

British firm GW Pharmaceuticals has revealed that it plans to reclaim the commercialisation rights to market its cannabis-based multiple sclerosis drug Sativex (delta-9-tetrahydrocannabinol and cannabidiol), known by the generic name nabiximols, in the UK.

3. US domestic supply of 150 drugs under threat from coronavirus outbreak

Disruption to the US drug production pipeline from the coronavirus could hurt its domestic supply of 150 drugs.

2. China approves Roche's Actemra to fight severe complications stemming from coronavirus

China has moved to authorise Roche’s Actemra (tocilizumab) as a treatment for severe complications from contracting the COVID-19 coronavirus in a bid to contain the ongoing national and global outbreak of the virus.

1. India reducing API exports due to coronavirus threatening global supply chain

India is set to reduce exports of active pharmaceutical ingredients (APIs) until further notice, due to fears of internal drug shortages that could occur from coronavirus.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches